Compare Natco Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA TTK HEALTHCARE NATCO PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 15.6 18.5 84.2% View Chart
P/BV x 3.1 1.5 206.6% View Chart
Dividend Yield % 1.5 1.0 139.6%  

Financials

 NATCO PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
TTK HEALTHCARE
Mar-19
NATCO PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,0801,215 88.9%   
Low Rs671610 110.0%   
Sales per share (Unadj.) Rs592.1444.4 133.2%  
Earnings per share (Unadj.) Rs188.417.2 1,092.4%  
Cash flow per share (Unadj.) Rs206.327.6 746.8%  
Dividends per share (Unadj.) Rs8.255.00 165.0%  
Dividend yield (eoy) %0.90.5 172.0%  
Book value per share (Unadj.) Rs833.6177.9 468.5%  
Shares outstanding (eoy) m36.9014.13 261.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.52.1 72.0%   
Avg P/E ratio x4.652.9 8.8%  
P/CF ratio (eoy) x4.233.0 12.8%  
Price / Book Value ratio x1.15.1 20.5%  
Dividend payout %4.429.0 15.1%   
Avg Mkt Cap Rs m32,31112,894 250.6%   
No. of employees `0004.82.3 209.0%   
Total wages/salary Rs m3,2561,307 249.1%   
Avg. sales/employee Rs Th4,522.52,715.7 166.5%   
Avg. wages/employee Rs Th674.0565.3 119.2%   
Avg. net profit/employee Rs Th1,439.0105.4 1,365.2%   
INCOME DATA
Net Sales Rs m21,8486,279 348.0%  
Other income Rs m40478 521.3%   
Total revenues Rs m22,2526,356 350.1%   
Gross profit Rs m9,284496 1,873.3%  
Depreciation Rs m662147 451.3%   
Interest Rs m15434 455.6%   
Profit before tax Rs m8,872393 2,259.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920149 1,289.5%   
Profit after tax Rs m6,952244 2,852.7%  
Gross profit margin %42.57.9 538.4%  
Effective tax rate %21.637.9 57.1%   
Net profit margin %31.83.9 819.8%  
BALANCE SHEET DATA
Current assets Rs m21,3072,717 784.2%   
Current liabilities Rs m5,9201,571 376.9%   
Net working cap to sales %70.418.3 385.7%  
Current ratio x3.61.7 208.1%  
Inventory Days Days7332 227.8%  
Debtors Days Days10747 228.3%  
Net fixed assets Rs m14,986991 1,512.2%   
Share capital Rs m369141 261.1%   
"Free" reserves Rs m30,3532,373 1,279.1%   
Net worth Rs m30,7602,514 1,223.4%   
Long term debt Rs m03 0.0%   
Total assets Rs m37,1514,158 893.5%  
Interest coverage x58.612.6 464.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.61.5 38.9%   
Return on assets %19.16.7 286.6%  
Return on equity %22.69.7 233.2%  
Return on capital %29.316.9 173.3%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m10,322225 4,583.4%   
Fx outflow Rs m2,97871 4,188.5%   
Net fx Rs m7,343154 4,765.6%   
CASH FLOW
From Operations Rs m4,636173 2,678.2%  
From Investments Rs m-11,15597 -11,559.6%  
From Financial Activity Rs m6,509-307 -2,118.1%  
Net Cashflow Rs m-18-38 47.7%  

Share Holding

Indian Promoters % 52.0 65.4 79.6%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 5.2 319.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 25.8 100.8%  
Shareholders   25,395 12,723 199.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  ALKEM LABORATORIES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 18, 2019 12:25 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - TORRENT PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS